SLDB

Solid Biosciences Inc. is a leading life sciences company dedicated to developing innovative gene therapies for Duchenne muscular dystrophy (DMD), a debilitating genetic disorder predominantly impacting young boys. Based in Cambridge, Massachusetts, the company is focused on addressing significant unmet medical needs through its advanced pipeline aimed at restoring functional dystrophin. By prioritizing translational science and leveraging collaborations within the DMD community, Solid Biosciences is committed to enhancing the quality of life for affected individuals and transforming treatment approaches in rare genetic diseases.